General
Preferred name
DROXIDOPA
Synonyms
SM5688 ()
DOPS ()
L-DOPS ()
Northera ()
L-threo-dops ()
P&D ID
PD014696
CAS
3916-18-5
1260173-94-1
23651-95-8
Tags
available
drug
prodrug
Approved by
FDA
First approval
2014
Drug indication
Neurogenic orthostatic hypotension
Hypotension
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
As droxidopa is a prodrug for noradrenaline, its effects will be through noradrenaline activation of adrenoceptors. The cellular effect is dependent upon adrenoceptor subtype expression on target cells.
(GtoPdb)
MOA
Droxidopa crosses the blood-brain barrier where it is converted to norepinephrine via decarboxylation by L-aromatic-amino-acid decarboxylase. Norephinephrine acts at alpha-adrenergic receptors as a vasoconstrictor and at beta-adrenergic receptors as a heart stimulator and artery dilator.
PRICE
65
DESCRIPTION
Droxidopa (L-DOPS) is an orally available prodrug of norepinephrine that is used in the treatment of symptomatic orthostatic hypotension due to neurogenic causes of autonomic failure.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
21
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
85
Molecular Weight
213.06
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
5
Rotatable Bonds
3
Ring Count
1
Aromatic Ring Count
1
cLogP
-0.46
TPSA
124.01
Fraction CSP3
0.22
Chiral centers
2.0
Largest ring
6.0
QED
0.43
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
Adrenergic Receptor
ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH
MOA
Adrenergic Receptor inhibitor
Norepinephrine Precursors
norepinephrine precursor
Member status
virtual
Indication
hypertension, Parkinson's Disease
Disease Area
cardiology, neurology/psychiatry
Pathway
GPCR/G protein
Neuroscience
Neuronal Signaling
Source data

